Little is known about the possible role of leukocytes in the pathogenesis of vasospasm. We hypothesized that vasoactive products released by leukocytes might produce constriction of atherosclerotic arteries. To test this hypothesis, we infused fmet-leu-phe (fMLP), a peptide that activates leukocytes to release their vasoactive products, into the perfused hind limb of normal and atherosclerotic cynomolgus monkeys. Infusion of fMLP did not change resistance of large arteries in normal monkeys. In contrast, fMLP produced pronounced constriction of large arteries in atherosclerotic monkeys. To determine whether leukotrienes, platelet-activating factor, or prostaglandin E^ (PGEJ, which are released by leukocytes, may contribute to leukocyte-induced vasoconstriction in atherosclerotic monkeys, we injected leukotriene D 4 , platelet-activating factor, and PGE^ intra-arterially into the perfused hind limb. Leukotriene D 4 and platelet-activating factor had minimal effects on large arteries in both normal and atherosclerotic monkeys. PGEj produced marked constriction of large arteries in atherosclerotic, but not normal, monkeys. Thus, pronounced constriction in atherosclerotic, but not normal, arteries during infusion of fMLP suggests that products released by leukocytes may mediate vasoconstriction in atherosclerotic vessels. Vasoconstrictor responses to PGEi are profoundly potentiated by atherosclerosis, which suggests that PGE^ may contribute to leukocyte-induced vasoconstriction. {Circulation Research 1989;65:1078-1086)
O bservations in patients 1 and experimental animals 2 ' 3 suggest that vasospasm is most likely to occur when atherosclerosis is present. Mechanisms by which atherosclerosis predisposes arteries to spasm are not clear. Aggregation of platelets, with release of vasoactive products, has been implicated in the pathogenesis of spasm. 3 -4 Little is known, however, about a possible role for leukocytes in the pathogenesis of spasm.
Atherosclerotic lesions contain many leukocytes, predominantly monocyte-macrophages, which are attached to the endothelium and are in the vessel wall. 5 - 6 Monocyte-macrophages release a variety of vasoactive substances, including thromboxane A 2 , prostaglandin E2 (PGE2), peptidoleukotrienes, and platelet-activating factor (PAF). 7 Furthermore, there may be decreased production of prostaglandin I 2 (PGI 2 ) and increased synthesis of PGE2 and thromboxane A 2 in atherosclerotic vessels compared with normal vessels. 8 -9 Thus, it is possible that leukocytes, either as blood-borne leukocytes or monocytemacrophages in the vessel wall, may play a role in spasm of atherosclerotic arteries.
The tripeptide ./V-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) is a potent activator of polymorphonuclcar leukocytes 10 and monocytemacrophages. 11 ' 12 fMLP induces leukocyte degranulation with resultant stimulation of arachidonic acid metabolism through interaction with a specific receptor. 13 A recent study of the isolated perfused rabbit heart demonstrated that injection of fMLP in noninfarcted hearts produced minimal coronary vasoconstriction, but after myocardial infarction, fMLP stimulated the release of thromboxane A 2 , PGE2, and peptidoleukotrienes with resultant coronary vasoconstriction.
14 The response to fMLP was attributed to activation of inflammatory cells that are present in the infarcted hearts. 14 In this study, we tested the hypothesis that, when leukocytes are activated by fMLP, vasoactive products released by leukocytes may produce constriction in atherosclerotic vessels. Recent work from our laboratory has shown that vasoconstrictor responses to thromboxane A2, a major product of leukocytes, are augmented by atherosclerosis. 15 We also tested the hypothesis that responses to three major products released by activated leukocytes, PGEj, leukotriene D 4 (LTD 4 ), and PAF are altered by atherosclerosis in a direction that would favor vasoconstriction.
Materials and Methods
Two groups of adult male Malaysian cynomolgus monkeys were studied. Sixteen normal monkeys were fed commercial laboratory chow (Purina monkey chow, Ralston Purina, Richmond, Indiana). Twelve monkeys were fed atherogenic diet, which contained cholesterol (1 mg/calorie) and fat (43% of total calories), for 19+0.5 months (mean±SEM). The monkeys weighed 5.4±0.2 kg in the normal group and 6.1±0.2 kg in the atherosclerotic group. At intervals of 3-4 months, the monkeys were sedated with ketamine hydrogen chloride (10 mg/kg i.m.), and a venous blood sample was obtained. Total cholesterol and trigrycerides were determined with the methods used by the Lipid Research Clinics Protocol for the AutoAnaryzer II (Technicon Instruments, Tarrytown, New York). Total leukocyte blood count and differential count were determined with a Technicon H-l or H-6000 (Technicon Instruments).
Hemodynamic Studies
At the time of study, the monkeys were sedated with ketamine (15 mg/kg i.m.) and anesthetized with chloralose (100 mg/kg i.v.). A tracheostomy was performed, and the monkeys were intubated and ventilated with room air and supplemental oxygen. Gallamine triethiodide (5 mg/kg i.v.) was given for paralysis of skeletal muscles, and heparin sodium (500 units/kg i.v.) was given for anticoagulation. Arterial blood gases and pH were monitored during each study and maintained at normal levels by adjustment of ventilation or injection of small amounts of sodium bicarbonate. Rectal temperature was maintained at 37-38° C with a heating pad.
A polyethylene catheter was inserted through the right brachial artery for measurement of aortic pressure and to obtain blood samples. Catheters were inserted into the right and left brachial veins for injections of fluids and drugs.
Through a laparotomy, the bifurcation of the abdominal aorta and the proximal left iliac artery was exposed and isolated. The left dorsal pedal artery also was exposed, and a PE-50 catheter was inserted retrogradely to measure pressure. A calibrated pulsatile perfusion pump (model 1210, Harvard Apparatus, South Natick, Massachusetts) was used to perfuse the left iliac artery at constant flow with blood from the abdominal aorta, and iliac perfusion pressure was measured continuously. When the pump was stopped, perfusion pressure decreased rapidly to 10-15 mm Hg, which indicates that vascular isolation was adequate. Baseline perfusion pressure of the hind limb was established by adjusting blood flow so that perfusion pressure was similar to the animal's mean arterial pressure. The difference between iliac pressure and dorsal pedal pressure at constant flow indicates resistance of large arteries of the limb. The method has been described in detail previously. 3 -16 At the end of the experiment, the leg was severed through the hip joint. The limb was weighed so that limb blood flow and vascular resistance could be expressed per 100 grams of limb.
We studied the effects of PGEj, PGI 2 , the chemotactic peptide fMLP, PAF (L-a-phosphatidylcholine, £-acetyl-y-0-alkyl), all from Sigma Chemical, St. Louis, Missouri, and LTD 4 (Merck-Frosst Laboratories, Pointe Claire-Dorval, Quebec, Canada).
PGE, (3x 10-'° and 3 x 10" 9 mol) and PAF (2x 10' 10 and 7xlO~1 0 mol) were injected as a 0.1-ml bolus into the iliac perfusion tubing. PGI 2 (1x10"' and 3xlO-9 mol/min) and fMLP (10~9, 10' 8 , and 10" 7 mol/min) were infused at 0.1 ml/min for 4 minutes into the iliac perfusion tubing. fMLP was administered after a 20-minute interval between doses. Higher doses of fMLP (>10~7 mol/min), which produce a systemic response with a decrease in arterial pressure, were not used in the protocol.
The maximal response to intra-arterial infusions of 10~9-10~7 mol/min fMLP was determined. Maximal responses occurred at 10" 9 mol/min in four normal and four atherosclerotic monkeys, at 10" 8 mol/min in one normal and one atherosclerotic monkey, and at 10" 7 mol/min in four normal and five atherosclerotic monkeys. When a vascular response to fMLP occurred, it was rarely possible to elicit a subsequent response at the same or higher dose, even after waiting 20-60 minutes. This phenomenon may be related to the prolonged binding of fMLP to the leukocyte receptor.
10 Injection of 0.1 ml vehicle or infusion at 0.1 ml/min vehicle for all the agonists had minimal hemodynamic effects. Maximal change in perfusion pressure and pressure in dorsal pedal artery was measured after bolus injections or after 4 minutes of infusion.
Studies In Vitro
Isolated vascular ring preparation. The iliac artery contralateral to the limb that was studied in vivo was isolated and excised. Vessels were cut into 5-mm ring segments and were suspended in a vertically oriented organ bath in 25 ml Kreb's buffer containing (mM) NaCl 118.3, KC1 4.7, CaCl 2 2.5, MgSO 4 1.2, KH 2 PO 4 1.2, NaHCO 3 25, EDTA calcium 0.026, and glucose 11.1, pH 7.40, aerated with 95% O 2 -5% CO 2 and maintained at 37° C. All studies were performed in the presence of propranolol (10~7 M). Tension was recorded with a linear force transducer (model FTO3c, Grass Instruments, Quincy, Massachusetts) or by an oscillographic recorder.
Over a period of 1 hour, the resting tension of the vascular ring was gradually increased until the optimal tension for generating force during isometric contraction was reached. At each tension, the vessel was exposed to potassium chloride (100 mM), and the tension was recorded. After each dose of potassium chloride, the baths were washed with fresh buffer. The resting tension was increased until additional doses of potassium chloride failed to increase the constrictor response. The vessels were left at this optimal resting tension throughout the remainder of the study.
Protocols. We examined cumulative responses to fMLP (10~1 0 -10~4 M) in vascular rings. fMLP was diluted with distilled water so that less than 0.1 ml was added to the bath for each dose. Vessels were preconstricted with a concentration of prostaglandin F^ (Sigma Chemical) that produced 30-50% of a predetermined maximal constrictor response. Between each concentration-response curve, vessels were washed three times with fresh buffer and were allowed to reequilibrate for at least 30 minutes. At the completion of each experiment, the vascular segment was immersed in fixative (2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.2) for approximately 5 minutes while still mounted on the isolated-ring apparatus. The vessel was then removed from the apparatus and maintained in fixative at 4° C for at least 24 hours. The vessels were then examined by scanning electron microscopy to confirm the presence of endothelium as described previously. 17 Morphological studies. The monkeys were killed with intravenous potassium chloride. The iliac and femoral artery vessels were removed, examined for gross lesions, and fixed by immersion in 10% buffered formalin. Specimens were taken from the proximal iliac artery for histological study of paraffinembedded transverse sections. Sections were stained with hematoxylin-eosin and Verhoeff-van Gieson's stain. Morphometric determination of the size of the intima and media was performed with an image analyzer, as described previously. 16 Statistical analysis. Mean values were analyzed with ANOVA general linear models procedure from SAS (SAS Institute, Inc., Cary, North Carolina). Comparisons of morphometric data were determined by the use of nonparametric Wilcoxon rank-sum test. Student's t test for unpaired groups was used for analysis of baseline hemodynamics, leukocyte count, and maximal fMLP responses. In the experiments with isolated vessels, Student's t test for unpaired groups was used to compare concentration- response curves at each concentration of drug. Statistical significance was considered as/><0.05.
Results

Plasma Lipids and Leukocyte Count
Plasma total cholesterol was 114±8 mg/dl (mean±SEM) in normal monkeys and 567±40 mg/ dl in atherosclerotic monkeys. Plasma triglycerides were less than 40 mg/dl in both groups.
Total peripheral leukocyte blood count was 10,800±l,200/mm 3 (mean±SEM) in normal monkeys and ll,600±4,700/mm 3 in atherosclerotic monkeys. The differential leukocyte count was similar in normal and atherosclerotic monkeys.
Morphologic Changes
In atherosclerotic monkeys, morphologic changes were similar to those described previously. 
Hemodynamic Studies
Baseline values. Large-artery resistance was significantly greater in atherosclerotic than in normal monkeys (Table 1) .
Responses to fMLP. The chemotactic peptide fMLP had minimal effects in the limb of normal monkeys (Figure 2, left panel) . In atherosclerotic monkeys, fMLP produced vasoconstriction (/><0.05 vs. normal monkeys; Figures 2 and 3 ).
There was minimal constriction of the largeartery segment in response to fMLP in normal monkeys ( Figure 2 , right panel). In contrast, there was marked constriction in atherosclerotic monkeys Q?<0.05 vs. normal monkeys). The vasoconstrictor response to fMLP was prolonged (usually 20-30 minutes) in atherosclerotic monkeys.
Responses to LTD 4 . LTD 4 produced vasodilatation in the limb of normal monkeys (Figure 4) . The dilator response to LTD 4 was impaired in atherosclerotic monkeys (/?<0.05 vs. normal monkeys). LTD 4 did not alter resistance of the large-artery segment in normal or atherosclerotic monkeys (data not included), which indicates that the dilator response to LTD 4 occurs in small vessels.
Responses to PGE 2 . PGE? produced vasodilatation in the limb of normal monkeys ( Figure 5 and left panel of Figure 6 ). The dilator response to PGEj was impaired in atherosclerotic monkeys (p<0.05 vs. normal monkeys) (Figures 6 and 7) . PGE2 produced minimal constriction of the large-artery segment in the limb of normal monkeys ( Figure 6 , right panel). There was striking potentiation of constrictor responses of the large artery segment in atherosclerotic monkeys (/?<0.05 vs. normal monkeys) ( Figure 6 Figure 8 ). PGI 2 had minimal effects on large arteries of the limb in both groups (data not included).
Responses to PAF. PAF produced vasodilatation in the limb (reduction in iliac perfusion pressure) in normal and atherosclerotic monkeys ( Figure 9 ). PAF had minimal effects on large arteries of the limb in both groups (data not included).
Responses in Isolated Vessels
Constrictor responses to potassium chloride (100 mM) were greater in normal vessels (3.6±0.5 g) than in atherosclerotic vessels (1.8±0.3 g,p<0.05). Peak responses to prostaglandin F^ also were greater in normal vessels (4.3±0.9 g) than in atherosclerotic vessels (2.1±0.3 g,p<0.05).
Responses to fMLP. fMLP had minimal effect in iliac arteries from normal and atherosclerotic monkeys. In eight normal monkeys, there was no response to fMLP at 10" 10 -10" 7 M. Constrictor responses of 9±6% (mean±SEM) were seen at 10" 6 M, 24±14% were seen at 10" f M, and 1±1% were seen at 10~" M. fMLP 10" 5 M produced profound 
FIGURE 4. Bar graphs showing changes in total limb resistance after intra-arterial injection of leukotriene D 4 (LTD 4 ). Values are mean±SEM in eight normal (N) and eight atherosclerotic (AS) monkeys. +p<0.05 vs. normal monkeys.
constrictor responses in two of the eight normal monkeys with no response in the other six monkeys. In 12 atherosclerotic monkeys, there was no response to fMLP at each concentration tested between 10-10 -10-4 M.
Discussion
These data suggest, first, that atherosclerosis affects vascular responses to activation of leukocytes in vivo. fMLP, a peptide which activates leukocytes to release their vasoactive products, produced marked constriction in large arteries in atherosclerotic, but not normal, monkeys. Second, responses to the vasoactive products produced by leukocytes were altered by atherosclerosis: vasoconstrictor responses to PGE2 are potentiated, and vasodilator responses to LTD 4 are impaired. Third, LTD 4 produces dilatation of small vessels but not large arteries. Impairment of dilator responses to LTD< by atherosclerosis provides evidence that atherosclerosis impairs responses of small vessels, even though small vessels do not develop atherosclerotic lesions.
Importance of Leukocytes
Formation of atherosclerotic lesions is characterized by adherence of blood-borne monocytes to the endothelium.
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- 20 As atherosclerotic lesions develop, cellular components consist primarily of monocytemacrophages. 5 -6 When activated, these cells can release a variety of vasoactive substances, including thromboxane A 2 , PGE2, peptidoleukotrienes, and PAF. 7 To determine whether leukocytes can initiate vascular responses in the limb, we infused fMLP. fMLP is a peptide that activates poh/morphonuclear leukocytes 10 and monocyte macrophages 11 ' 12 by interaction with a specific receptor. 10 - 21 Smooth muscle cells, fibroblasts, and epithelial cells do not have receptors for fMLP. 22 Although endothelial cells have receptors for fMLP, receptor binding is involved in membrane transport rather than activation of specific metabolic pathways. 22 Thus, it appears that fMLP may be used to specifically activate leukocytes without direct effects on vascular smooth muscle. In a previous study, effects of fMLP were examined in rabbits with left ventricular infarction and were followed by ex vivo cardiac perfusion.
14 fMLP released thromboxane, peptidoleukotrienes, and PGEj and produced coronary vasoconstriction in infarcted, but not normal, hearts. The increased synthesis of prostaglandins in infarcted hearts was temporally associated with the influx of inflammatory cells into the infarcted tissue. The predominant inflammatory cell types seen by histological analysis were polymorphonuclear leukocytes and macrophages. The authors proposed that coronary vasoconstrictor responses to fMLP were mediated at least in part by metabolites of arachidonic acid released from activated inflammatory cells. 14 Constrictor responses of large arteries during infusion of fMLP in the limb of atherosclerotic monkeys suggest that activation of leukocytes, with release of vasoactive substances, 23 -24 played an important role in the response to fMLP. In this blood-perfused system, fMLP may activate leukocytes that are circulating in the blood, attached to the endothelium, or present in the vessel wall. In a recent study in normal rabbits, fMLP produced coronary vasoconstriction in blood-perfused hearts in vivo and had no effect in the isolated KrebsHenseleit-perfused heart. 23 This finding suggests that circulating cellular elements mediate vasocon- stricter responses to fMLP. Our finding that fMLP has little effect in isolated vessels from atherosclerotic monkeys in vitro also suggests that circulating cellular elements may be of greater importance in the response to fMLP than monocyte-macrophages in the vessel wall.
Mechanisms of Altered Vascular Responses
Substances that are released by leukocytes and thus are possible mediators of leukocyte-induced vasoconstrictor responses to fMLP in atherosclerotic monkeys include thromboxane A2, PGE2, peptidoleukotrienes, platelet-derived growth factor, 26 and hydroxylated eicosatetraenoic acids. 27 Vasoconstrictor responses to the thromboxane A 2 analogue U46619 are augmented by atherosclerosis. 15 Thus, release of thromboxane A 2 may contribute to leukocyte-induced vasoconstriction.
PGE2 is a potent vasodilator in the hind limb of rabbits 28 and dogs, 29 but it produces vasoconstriction in isolated bovine, canine, and human coronary arteries. 30 Vascular responses to PGE2 may be modulated by endothelium since removal of endothelium augments the vasoconstrictor response to PGE2 in canine basilar arteries. 31 In the present study, vasodilator responses to PGI 2 , which are not endothelium dependent, were preserved in atherosclerotic monkeys. Atherosclerosis produces a functional defect in endothelium-dependent relaxation. 17 - 32 It is possible that impairment of endothelium-dependent relaxation by atherosclerosis may contribute to augmentation of vasoconstrictor responses to PGE2. Thus, PGE2 may contribute to leukocyte-induced vasoconstriction in atherosclerotic vessels.
Platelets have been implicated in the pathophysiology of vasospasm. 3 -4 It is unlikely that vascular responses to PGE^ and fMLP were due to activation of platelets since PGE2 and fMLP do not appear to produce platelet aggregation. We have examined separately the vascular responses to several mediators that are released when leukocytes are activated. It is possible that simultaneous release of these vasoactive agents could produce a synergistic response. 42 Thus, subthreshold doses of individual mediators may have minimal effect, but the simultaneous release of small concentrations of multiple mediators may produce profound vasoconstriction.
Recent evidence suggests that hypercholesterolemia augments macrophage function with enhanced release of products. 43 It is possible that responses to fMLP in atherosclerotic monkeys may be related to enhanced release of vascular products as well as altered responses to these products.
Implications
Arterial spasm or enhanced vasoconstriction has a predilection for sites at which atherosclerosis is present. Atherosclerotic lesions contain many leukocytes, which are predominantly monocytemacrophages attached to the endothelium and within the vessel wall. Our findings indicate that activation of leukocytes, either as blood-borne leukocytes or monocyte-macrophages in the vessel wall, produces pronounced vasoconstriction in atherosclerotic vessels. Leukocyte-induced vasoconstriction may be mediated by thromboxane A 2 and PGE2, or could be the result of a synergistic response to several vasoactive products. We propose that altered responses to activation of leukocytes may contribute to the susceptibility to vasospasm that is characteristic of atherosclerosis.
